Concepedia

Thomas O’Hare

TO

Statistics

Publications

70

Citations

9.2K

H-Index

42

Active since

1997

Affiliations

Oregon Health & Science University(Current)

Howard Hughes Medical Institute

Huntsman Cancer Institute

University of Utah

Ariadne Diagnostics (United States)

Thomas O’Hare is an author at Oregon Health & Science University specializing in molecular oncology, medicine, and oncology.

Publications per year

1997–2021

70

Publications

70

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu et al. · Cancer Cell · 2009 · 1.2K citations · Full text

, , +9

<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

Thomas O’Hare, Denise K. Walters, Eric P. Stoffregen et al. · Cancer Research · 2005 · 1K citations · Full text

, , +10

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, Hagop M. Kantarjian, Neil P. Shah et al. · New England Journal of Medicine · 2012 · 770 citations · Full text

, , +13

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

Thomas O’Hare, Christopher A. Eide, Michael W. Deininger · Blood · 2007 · 640 citations · Full text

, , +16

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations

Heather A. Bradeen, Christopher A. Eide, Thomas O’Hare et al. · Blood · 2006 · 401 citations · Full text

, , +8

1–5 of 70